Stock Region Penny Picks
Welcome Back, Stock Region Family!
Welcome Back, Stock Region Family!
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The following newsletter is for informational and educational purposes only. We are not licensed financial advisors. The opinions expressed here are our own and do not constitute financial advice. Always do your own research and consult with a professional before making any investment decisions. Trading stocks carries significant risk.
The market never sleeps, and today is serving up some incredibly spicy catalysts. From massive biotech breakthroughs to space exploration and electric boats, there is a lot to unpack. Let’s dive right into the updates that have us leaning forward in our chairs this morning.
$PERF - Taking it Private?
Perfect has received a preliminary, non-binding “going private” proposal. Buyout chatter always gets the blood pumping! We love the potential for a quick premium pop here, but stay grounded. “Non-binding” means the deal can still fall through, so watch the volume closely and don’t get caught holding the bag if negotiations stall.
$BURU - Real Impact, Real Revenue
NUBURU and Tekne are officially launching Phase 1 revenue by producing the GRAELION Platform for Ukraine. This is one of those rare moments where investing intersects with profound global impact. Seeing a company secure early revenue while supporting a major real-world cause gives us serious conviction. This is a massive momentum play.
$VNRX & $AIM - The Biotech Heavyweights
Biotech is bringing tears to our eyes today—literally, these are life-saving updates.
$VNRX just reported a 99% purity breakthrough in isolating cancer DNA via liquid biopsy. That is a staggering medical achievement. When the science is this good, the market usually pays attention.
$AIM was actually halted on the upside after scoring a final patent approval in Japan for combining Ampligen with checkpoint inhibitors. The halt tells you exactly how hungry buyers are for this news. Watch for the wild price action when trading resumes!
$OVID, $ARTL, & $SER - The Trial Grind
$ARTL is getting a fully-funded third-party study for Glaucoma. We absolutely love “fully funded.” It means progress without burning through their own cash reserves.
$SER secured a $30 million private placement for their Advanced Parkinson’s Disease trial. Yes, private placements can cause short-term dilution jitters, but locking in $30 million to advance a registrational trial is a massive long-term win.
$OVID dropped a heavy mix of new data, trial clearances, and their 2025 financials. Earnings reports always bring wild volatility, so tread carefully while the market digests the numbers.
$MNTS & $VMAR - Transportation of the Future
$MNTS just bagged a NASA contract to design a Solar Sail Demonstration Mission. Let that sink in: Solar Sails. Space tech always carries a high risk, but the sheer cool factor and government backing make this a thrilling watchlist addition.
$VMAR is seeing a sharp spike in demand for electric boats. The EV craze is finally hitting the water! With strong early 2026 momentum, this is a fantastic clean energy trend to ride.
Keep your eyes glued to the charts today. Set your stop losses, take profits when you have them, and let’s make it a green day!
Disclaimer: The stocks mentioned in this newsletter are highly volatile. The information provided is based on recent news and our personal commentary, which may not encompass all factors affecting a stock’s price. Stock Region and its writers hold no liability for any financial losses incurred. Trade smart, manage your risk, and never invest money you cannot afford to lose.